FDA · Enforcement report ·
FDA classifies a recall for cyproheptadine syrup with crystallization
If you were prescribed Rising cyproheptadine hydrochloride syrup, the FDA reports a class II issue involving crystallizing medication and floating particles.
If you take Rising cyproheptadine hydrochloride syrup, the US Food and Drug Administration has classified this product for recall.
The issue described is crystallizing medication (precipitate) with particles floating in the bottle.
The product was distributed nationwide in the U.S. The FDA’s notice was published 2026-07-29.